Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention (SAVI-PCI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01522417

Recruitment Status : Recruiting

First Posted : January 31, 2012

Last Update Posted : March 12, 2018

See Contacts and Locations

Sponsor:

Collaborator:

SCRI Development Innovations, LLC

Information provided by (Responsible Party):

Medicure

Study Description

Brief Summary:

The purpose this study is to assess whether a tirofiban regimen of a high-dose bolus plus a shortened infusion duration compared to label-dosing eptifibatide in patients undergoing percutaneous coronary intervention (PCI) is associated with a non-inferior composite rate of death, PCI-related myocardial infarction, urgent target vessel revascularization or in-hospital major bleeding within 48 hours following PCI or hospital discharge, whichever comes first.

Condition or disease	Intervention/treatment	Phase
Myocardial Infarction Acute Coronary Syndromes Unstable Angina	Drug: Short Tirofiban Drug: Eptifibatide Drug: Long Tirofiban	Phase 2

Study Design


Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	550 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	None (Open Label)
Primary Purpose:	Treatment
Official Title:	A Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy of Tirofiban Using a High-Dose Bolus Plus a Shortened Infusion Duration Versus Label-Dosing Eptifibatide in Patients Undergoing Percutaneous Coronary Intervention
Study Start Date :	April 2012
Estimated Primary Completion Date :	March 2019
Estimated Study Completion Date :	July 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Attack

Drug Information available for: Tirofiban hydrochloride Tirofiban Eptifibatide

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Short Tirofiban (Aggrastat) Tirofiban (Aggrastat) will be dosed as a 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI. Patients will receive tirofiban (Aggrastat) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines).	Drug: Short Tirofiban 25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI. Other Name: Aggrastat
Active Comparator: Eptifibatide (Integrilin) Eptifibatide (Integrilin) will be dosed as a 180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first. Patients will receive eptifibatide (Integrilin) on a background of dual oral anti-platelet agents and unfractionated heparin (50 U/kg and repeat dosing per protocol guidelines).	Drug: Eptifibatide 180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first. Other Name: Integrilin
Experimental: Long Tirofiban (Aggrastat) (Enrolment Completed) Tirofiban (Aggrastat) will be dosed as a 25 ug/kg i.v. bolus followed by a 0.15 ug/kg/min i.v. infusion for 12 to 18 hours post PCI. Patients will receive tirofiban (Aggrastat) on a background of dual oral anti-platelet agents and unfractionated heparin (50U/kg and repeat dosing per protocol guidelines).	Drug: Long Tirofiban 25 ug/kg i.v. bolus followed by a 0.15 ug/kg/min i.v. infusion for 12 to 18 hours post-PCI. Other Name: Aggrastat

Outcome Measures

Primary Outcome Measures :

The composite incidence of death, PCI-related myocardial infarction, urgent target vessel revascularization or major bleeding [ Time Frame: 48 hours ]

Secondary Outcome Measures :

The composite incidence of death, PCI-related myocardial infarction or urgent target vessel revascularization [ Time Frame: 48 hours ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Age ≥18 years of age
Scheduled to undergo PCI with an FDA, approved or cleared device (stent or procedures such as balloon angioplasty, rotoblation, AngioSculpt, laser atherectomy,etc.) in one or more native coronary target lesions
Written informed consent

Exclusion Criteria:

Primary PCI for STEMI as index procedure
Prior STEMI within 48 hours before randomization
Prior PCI within 30 days before randomization
Planned staged PCI within the subsequent 24 hours after index PCI
Use of abciximab within 7 days before randomization
Use of tirofiban or eptifibatide within 12 hours before randomization
Use of low-molecular weight heparin within 12 hours before randomization
Use of bivalirudin within 12 hours before randomization

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01522417

Contacts


Contact: Debbie Douglas, PhD	204-594-3624	ddouglas@medicure.com

Locations


United States, Florida
Osceola Regional Medical Center	Completed
Kissimmee, Florida, United States, 34741
Northside Hospital	Completed
Saint Petersburg, Florida, United States, 33709
United States, Georgia
Emory University Hospital Midtown	Completed
Atlanta, Georgia, United States, 30308
Emory University Hospital	Completed
Atlanta, Georgia, United States, 30322
North Georgia Heart Center	Completed
Gainesville, Georgia, United States, 30501
Redmond Regional Medical Center	Recruiting
Rome, Georgia, United States, 30165
Principal Investigator: Hector R Picon, MD
Archbold Medical Center	Completed
Thomasville, Georgia, United States, 31792
United States, New York
Lenox Hill Hospital	Completed
New York, New York, United States, 10075
United States, Oklahoma
University of Oklahoma Health Sciences Center	Recruiting
Oklahoma City, Oklahoma, United States, 73104
Principal Investigator: Mazen Abu-Fadel, MD
United States, Pennsylvania
Doylestown Hospital	Completed
Doylestown, Pennsylvania, United States, 18901
Penn Presbyterian Medical Center	Completed
Philadelphia, Pennsylvania, United States, 19104
United States, Tennessee
Centennial Heart	Recruiting
Nashville, Tennessee, United States, 37203
Principal Investigator: Brian K Jefferson, MD
United States, Virginia
Chippenham Hospital	Recruiting
Richmond, Virginia, United States, 23225
Principal Investigator: Michael L Arcarese, MD

Sponsors and Collaborators

Medicure

SCRI Development Innovations, LLC

Investigators


Principal Investigator:	Steven V Manoukian, MD	SCRI Development Innovations, LLC

More Information


Responsible Party:	Medicure
ClinicalTrials.gov Identifier:	NCT01522417 History of Changes
Other Study ID Numbers:	Medicure 11002
First Posted:	January 31, 2012 Key Record Dates
Last Update Posted:	March 12, 2018
Last Verified:	March 2018

Additional relevant MeSH terms:


Platelet Aggregation Inhibitors Infarction Myocardial Infarction Acute Coronary Syndrome Angina, Unstable Ischemia Pathologic Processes Necrosis Myocardial Ischemia Heart Diseases Cardiovascular Diseases Vascular Diseases	Angina Pectoris Chest Pain Pain Neurologic Manifestations Nervous System Diseases Signs and Symptoms Tirofiban Eptifibatide Fibrinolytic Agents Fibrin Modulating Agents Molecular Mechanisms of Pharmacological Action

To Top